SEC Comment Letter for IGC Pharma, Inc. (IGC) (CIK 0001326205) (IGC) — Apr 3, 2017
IGC Pharma, Inc. (IGC) (CIK 0001326205)
Date: April 3, 2017 · CIK: 0001326205 · Accession: 0000000000-17-011138
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-32830
Referenced dates: March 30, 2017
Letter
Mail Stop 3030 April 3, 2017 Via E -mail Ram Mukunda Chief Executive Officer India Globalization Capital, Inc. 4336 Montgomery Avenue Bethesda, MD 20814
Re: India Globalization Capital, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 8, 2017 File No. 001-32830
Dear Mr. Mukunda :
We note from your letter dated March 30, 2017 that you have cancelled the shareholders meeting that was to be held on March 31, 2017 and you will not be following up the preliminary proxy statement with a definitive proxy statement. Therefore , we are terminating our review of the preliminary proxy statement, and will, as we deem appropriate, release publicly, through the agency’s EDGAR system, all correspondence, including this letter, relating to the review of your filing, consistent with the staff’s decision to publicly release comment and response letters relating to disclosure filings it has revi ewed. We remind you that the company and its management are responsible for the accuracy and adequacy of the ir disclosure s, notwithstanding any review, comments, action or absence of action by the staff .
Sincerely,
/s/ Russell Mancuso
Show Raw Text
Mail Stop 3030 April 3, 2017 Via E -mail Ram Mukunda Chief Executive Officer India Globalization Capital, Inc. 4336 Montgomery Avenue Bethesda, MD 20814 Re: India Globalization Capital, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 8, 2017 File No. 001-32830 Dear Mr. Mukunda : We note from your letter dated March 30, 2017 that you have cancelled the shareholders meeting that was to be held on March 31, 2017 and you will not be following up the preliminary proxy statement with a definitive proxy statement. Therefore , we are terminating our review of the preliminary proxy statement, and will, as we deem appropriate, release publicly, through the agency’s EDGAR system, all correspondence, including this letter, relating to the review of your filing, consistent with the staff’s decision to publicly release comment and response letters relating to disclosure filings it has revi ewed. We remind you that the company and its management are responsible for the accuracy and adequacy of the ir disclosure s, notwithstanding any review, comments, action or absence of action by the staff . Sincerely, /s/ Russell Mancuso Russell Mancuso Branch Chief Office of Electronics and Machinery